Experience

Oncoinvent AS

• Norway
• Biotechnology Research
• 1 - 100 Employee

• Senior Research Scientist

  • Jan 2021 - Present

  Development and optimization of therapeutic antibodies against several types of cancer. In vitro and in vivo testing, humanization, addressing antibody liabilities. Development and optimization of therapeutic antibodies against several types of cancer. In vitro and in vivo testing, humanization, addressing antibody liabilities.



Ragon Institute of Mass General, MIT, and Harvard

• United States
• Research Services
• 100 - 200 Employee

• Postdoctoral Fellow

  • May 2019 - Jan 2021

  Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA 2019-2022 Postdoctoral fellow, -Investigated human antibody-producing B cell behavior in vivo to determine their affinity maturation and hypermutation capacity to target various antigens; characterized such antibodies in detail and used in vivo -Utilized cellular immunology, serology and flow cytometry to measure significant increase in antibody affinity to antigens in order to uncover the increase in affinity for broadly neutralizing antibodies; such antibodies can be used as therapies in patients Show less



Yale University School of Medicine

• United States
• Research Services
• 700 & Above Employee

• Senior Postdoctoral Fellow

  • Feb 2012 - Dec 2018

  Yale University, School of Medicine, Dept of Internal Medicine, New Haven, CT 2012-2018 Senior Postdoctoral Fellow, Laboratory of Dr Erol Fikrig -Identified and investigated in detail novel host-pathogen interactions in order to target human pathogen using humanized mouse models (FNRG) and characterized and described novel B cell antibodies against the antigens -Utilized biochemistry, molecular biology and immunology with microbiology to study antibody- pathogen interactions in order to develop novel human malaria vaccine candidate -Worked as group leader who directed the project activities and presented the data Show less



Vanderbilt University

• United States
• Higher Education
• 700 & Above Employee

• Graduate Student; defended PhD Thesis

  • Aug 2005 - Dec 2011

  Vanderbilt University, School of Medicine, Department of Immunology and 2005-2011 Microbiology, Nashville, TN, USA, Ph.D. student, Laboratory of Dr Sebastian Joyce Published the first report of a paradigm shift in T cell biology and effector function; specifically, that components of the MHC I pathway can negatively regulate CD4 T cell activation, effector function and cytokine production Such findings lead to altered CD4 T cells responses to microbial, cancer and transplantation antigens that may lead to novel T cell based vaccine design against tumors and pathogens Greatly utilized molecular, cellular immunology and biochemical approaches to study cytokine production and its role during immune processes where CD8+ dendritic cells (DCs) present antigens to CD8 and CD4 T cells leading to their activation and immune effector function Show less